JP6373444B1 - Amnion-derived raw material manufacturing method, cosmetic manufacturing method, and health food manufacturing method - Google Patents
Amnion-derived raw material manufacturing method, cosmetic manufacturing method, and health food manufacturing method Download PDFInfo
- Publication number
- JP6373444B1 JP6373444B1 JP2017093908A JP2017093908A JP6373444B1 JP 6373444 B1 JP6373444 B1 JP 6373444B1 JP 2017093908 A JP2017093908 A JP 2017093908A JP 2017093908 A JP2017093908 A JP 2017093908A JP 6373444 B1 JP6373444 B1 JP 6373444B1
- Authority
- JP
- Japan
- Prior art keywords
- amniotic membrane
- amnion
- placenta
- separation
- draining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001691 amnion Anatomy 0.000 title claims abstract description 313
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 31
- 235000013402 health food Nutrition 0.000 title claims abstract description 27
- 239000002537 cosmetic Substances 0.000 title claims abstract description 21
- 239000002994 raw material Substances 0.000 title claims description 46
- 210000002826 placenta Anatomy 0.000 claims abstract description 115
- 238000000926 separation method Methods 0.000 claims abstract description 74
- 238000007710 freezing Methods 0.000 claims abstract description 58
- 230000008014 freezing Effects 0.000 claims abstract description 58
- 238000010257 thawing Methods 0.000 claims abstract description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000463 material Substances 0.000 claims abstract description 35
- 238000005406 washing Methods 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims description 76
- 238000000605 extraction Methods 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 28
- 241000283086 Equidae Species 0.000 claims description 11
- 108091005507 Neutral proteases Proteins 0.000 claims description 8
- 102000035092 Neutral proteases Human genes 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- 108090000145 Bacillolysin Proteins 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 238000000354 decomposition reaction Methods 0.000 claims description 3
- 230000003712 anti-aging effect Effects 0.000 abstract description 15
- 230000000052 comparative effect Effects 0.000 description 25
- 230000008569 process Effects 0.000 description 23
- 241000283073 Equus caballus Species 0.000 description 14
- 239000000843 powder Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000035622 drinking Effects 0.000 description 9
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 8
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 241000282887 Suidae Species 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000036548 skin texture Effects 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000011344 liquid material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- -1 the extraction step Substances 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Abstract
【課題】 従来の胎盤由来原料よりもアンチエイジング効果に有用な成分が多く含まれる羊膜由来原料の製造方法、並びに羊膜由来原料が配合された化粧品及び健康食品を提供すること。
【解決手段】 採集した胎盤及び羊膜を凍結する分離前凍結工程１０と、胎盤及び羊膜を流水にて解凍する分離前解凍工程１１と、胎盤及び羊膜の水切りを行う分離前水切工程１２と、胎盤と羊膜を分離する分離工程１３と、羊膜を水洗いする羊膜水洗工程１４と、羊膜の水切りを行う羊膜水切工程１５と、羊膜を細断する羊膜細断工程１６と、羊膜を凍結する羊膜凍結工程１７と、羊膜を解凍する羊膜解凍工程１８とを有する。
【選択図】 図１PROBLEM TO BE SOLVED: To provide a method for producing an amnion-derived material containing more components useful for an anti-aging effect than conventional placenta-derived materials, and cosmetics and health foods containing the amniotic material-derived materials.
A pre-separation freezing step 10 for freezing collected placenta and amniotic membrane, a pre-separation thawing step 11 for thawing the placenta and amniotic membrane with running water, a pre-separation draining step 12 for draining the placenta and amniotic membrane, and a placenta. And amnion washing step 14 for washing the amniotic membrane, an amnion draining step 15 for draining the amniotic membrane, an amniotic shredding step 16 for shredding the amniotic membrane, and an amniotic membrane freezing step for freezing the amniotic membrane 17 and an amniotic membrane thawing step 18 for thawing the amniotic membrane.
[Selection] Figure 1
Description
本発明は、ヒト、ブタ、ウマ又はヒツジなどの哺乳動物の羊膜を原料とする羊膜由来原料の製造方法、並びに羊膜由来原料を配合した化粧品及び健康食品に関する。 The present invention relates to a method for producing an amnion-derived raw material from amnion of mammals such as humans, pigs, horses or sheep, and a cosmetic and health food containing the amniotic-derived raw material.
従来、哺乳動物の胎盤を由来原料とする胎盤（プラセンタ）エキス等の胎盤由来原料の製造方法が知られている。
例えば特許文献１には、ヒト、ウシ、ブタ又はヒツジの胎盤を凍結してミンチ化し、融解し、水洗した後、遠心または濾過により脱水して得た脱水胎盤を、水、アルカリプロテアーゼ等を加えて、加熱、撹拌を行うことで酵素加水分解反応を起こし、さらに、加熱した後、反応を停止させて室温で一晩放置し、上澄液を採取して濾過し、濾液をエチルアルコールで処理してエチルアルコール溶出液にし、溶出液を減圧濃縮したものを凍結乾燥して粉末にする胎盤エキスからなる抗アレルギー剤の製造方法が開示されている。
また、特許文献２には、血液、汚物及び臭い部位の除去を含む前処理をした胎盤と、前処理後の胎盤重量に対して０．２重量％〜２重量％のプロテアーゼを含む酵素とを、可撓性を有する袋体に内挿して真空包装する工程と、真空包装した袋体を、５０ＭＰａ以上〜２００ＭＰａ未満の圧力で、２０度〜５０度の範囲内でプロテアーゼを含む酵素の至適温度に制御した状態で、１日〜３日保持する抽出工程と、袋体内の内容物からプラセンタエキス原液を分離する固液分離工程とを有するプラセンタエキスの製造方法が開示されている。
また、特許文献３には、酵素消化過程における煩雑さの解消を目的として、ヒト又はブタの胎盤を、特定の耐熱性中性タン白質分解酵素を使用して酵素消化するプラセンタエキスの製造方法が開示されている。
Conventionally, a method for producing a placenta-derived material such as a placenta (placenta) extract using a mammalian placenta as a material is known.
For example, Patent Document 1 discloses that a placenta of human, cow, pig or sheep is frozen and minced, thawed, washed with water, dehydrated by centrifugation or filtration, and then added with water, alkaline protease or the like. Then, the enzyme hydrolysis reaction is caused by heating and stirring. After the heating, the reaction is stopped and the reaction is stopped and left overnight at room temperature. The supernatant is collected and filtered, and the filtrate is treated with ethyl alcohol. Thus, a method for producing an antiallergic agent comprising a placenta extract that is made into an ethyl alcohol eluate and the eluate concentrated under reduced pressure is lyophilized to a powder is disclosed.
Patent Document 2 describes a placenta that has been pretreated including removal of blood, dirt, and odorous sites, and an enzyme that contains 0.2 wt% to 2 wt% protease with respect to the placental weight after the pretreatment. And the step of vacuum packaging by interpolating into a flexible bag body, and the optimization of an enzyme containing a protease within a range of 20 degrees to 50 degrees at a pressure of 50 MPa to less than 200 MPa. There is disclosed a method for producing a placenta extract, which includes an extraction step that is maintained for 1 to 3 days under temperature control, and a solid-liquid separation step that separates a placenta extract stock solution from the contents in the bag.
Patent Document 3 discloses a method for producing a placenta extract in which human or porcine placenta is enzymatically digested with a specific heat-resistant neutral protein degrading enzyme for the purpose of eliminating the complexity of the enzymatic digestion process. It is disclosed.
胎盤由来原料は、たんぱく質、アミノ酸、ビタミン、ミネラル、酵素、核酸及び成長因子（ＥＧＦ等）等の成分が含まれることにより、皮膚代謝の促進、活性酸素消去、肝機能強化、抗炎症作用及び免疫賦活といったアンチエイジング効果があり、化粧品や健康食品等の原料として活用されている。
しかし、さらにアンチエイジング効果に優れた化粧品や健康食品等を提供するため、有用成分がより多く含まれるエキス等の開発が期待されている。
Placenta-derived materials contain ingredients such as proteins, amino acids, vitamins, minerals, enzymes, nucleic acids, and growth factors (EGF, etc.), thereby promoting skin metabolism, eliminating active oxygen, enhancing liver function, anti-inflammatory and immune It has an anti-aging effect such as activation and is used as a raw material for cosmetics and health foods.
However, in order to provide cosmetics, health foods and the like that are further excellent in anti-aging effects, development of extracts containing more useful components is expected.
そこで、本発明は、従来の胎盤由来原料よりもアンチエイジング効果に有用な成分が多く含まれるエキス等の製造方法、並びにそのエキス等が配合された化粧品及び健康食品を提供することを目的とする。 Then, this invention aims at providing the manufacturing method of extract etc. in which many components useful for an anti-aging effect are contained rather than the conventional placenta origin raw material, and the cosmetics and health food by which the extract etc. were mix | blended. .
請求項１記載の本発明の羊膜由来原料の製造方法は、採集した胎盤及び羊膜を凍結する分離前凍結工程と、前記分離前凍結工程の後に、前記胎盤及び前記羊膜を流水にて解凍する分離前解凍工程と、前記分離前解凍工程の後に、前記胎盤及び前記羊膜の水切りを行う分離前水切工程と、前記分離前水切工程の後に、前記胎盤と前記羊膜を分離する分離工程と、前記分離工程の後に、前記羊膜を水洗いする羊膜水洗工程と、前記羊膜水洗工程の後に、前記羊膜の水切りを行う羊膜水切工程と、前記羊膜水切工程の後に、前記羊膜を細断し、細断した前記羊膜を再度水切りする羊膜細断工程と、前記羊膜細断工程の後に、前記羊膜を凍結する羊膜凍結工程と、前記羊膜凍結工程の後に、前記羊膜を解凍する羊膜解凍工程と、前記羊膜解凍工程の後に、前記羊膜を分解抽出してエキスを得る抽出工程とを有し、前記抽出工程は、前記羊膜に精製水及び中性プロテアーゼを加え、抽出温度を３０度以上７０度以下、抽出時間を１時間以上１０時間以下としたものであり、前記胎盤及び前記羊膜は、ウマから採集されたものであることを特徴とする。
請求項２記載の本発明の羊膜由来原料の製造方法は、採集した胎盤及び羊膜を凍結する分離前凍結工程と、前記分離前凍結工程の後に、前記胎盤及び前記羊膜を流水にて解凍する分離前解凍工程と、前記分離前解凍工程の後に、前記胎盤及び前記羊膜の水切りを行う分離前水切工程と、前記分離前水切工程の後に、前記胎盤と前記羊膜を分離する分離工程と、前記分離工程の後に、前記羊膜を水洗いする羊膜水洗工程と、前記羊膜水洗工程の後に、前記羊膜の水切りを行う羊膜水切工程と、前記羊膜水切工程の後に、前記羊膜を細断し、細断した前記羊膜を再度水切りする羊膜細断工程と、前記羊膜細断工程の後に、前記羊膜を凍結する羊膜凍結工程と、前記羊膜凍結工程の後に、前記羊膜を解凍する羊膜解凍工程と、前記羊膜解凍工程の後に、前記羊膜を分解抽出してエキスを得る抽出工程とを有し、前記抽出工程は、前記羊膜の凍結と融解を所定回数繰り返して水溶性画分を分離するものであり、前記胎盤及び前記羊膜は、ウマから採集されたものであることを特徴とする。
請求項３記載の本発明の化粧品の製造方法は、請求項１又は請求項２に記載の羊膜由来原料の製造方法によって得られた羊膜由来原料を配合することを特徴とする。
請求項４記載の本発明の健康食品の製造方法は、請求項１又は請求項２に記載の羊膜由来原料の製造方法によって得られた羊膜由来原料を配合することを特徴とする。
The method for producing an amnion-derived material of the present invention according to claim 1 includes a pre-separation freezing step of freezing the collected placenta and amniotic membrane, and a separation in which the placenta and the amniotic membrane are thawed with running water after the pre-separation freezing step. A pre-thawing step, a pre-separation draining step for draining the placenta and the amniotic membrane after the pre-separation thawing step, a separation step for separating the placenta and the amniotic membrane after the pre-separation draining step, and the separation After the step, the amniotic membrane rinsing step for washing the amniotic membrane, the amniotic membrane draining step for draining the amniotic membrane after the amniotic membrane rinsing step, and after the amniotic membrane draining step, the amniotic membrane is shredded and chopped Amniotic membrane shredding step for draining the amniotic membrane again , Amniotic membrane freezing step for freezing the amniotic membrane after the amniotic membrane shredding step, Amniotic membrane thawing step for thawing the amniotic membrane after the amniotic membrane freezing step, and the amniotic membrane thawing step After The amnion decomposition extracted and possess an extraction step of obtaining extract, the extraction step, purified water and neutral proteases into the amnion was added, extraction temperature of 30 degrees 70 degrees or less, the extraction time 1 hour The placenta and the amniotic membrane are collected from horses .
The method for producing an amnion-derived material of the present invention according to claim 2 includes a pre-separation freezing step for freezing the collected placenta and amniotic membrane, and a separation for thawing the placenta and the amniotic membrane with running water after the pre-separation freezing step. A pre-thawing step, a pre-separation draining step for draining the placenta and the amniotic membrane after the pre-separation thawing step, a separation step for separating the placenta and the amniotic membrane after the pre-separation draining step, and the separation After the step, the amniotic membrane rinsing step for washing the amniotic membrane, the amniotic membrane draining step for draining the amniotic membrane after the amniotic membrane rinsing step, and after the amniotic membrane draining step, the amniotic membrane is shredded and chopped Amniotic membrane shredding step for draining the amniotic membrane again, Amniotic membrane freezing step for freezing the amniotic membrane after the amniotic membrane shredding step, Amniotic membrane thawing step for thawing the amniotic membrane after the amniotic membrane freezing step, and the amniotic membrane thawing step After , And a extraction step of obtaining extract the amniotic membrane degradation extracted and the extraction process state, and are not to separate the water-soluble fraction by repeating a predetermined number of times freezing and thawing of the amnion, the placenta and the amniotic membrane is characterized der Rukoto those collected from horses.
Cosmetic manufacturing method of the present invention according to claim 3, characterized by blending the amnion-derived raw material obtained by the manufacturing method of the amnion-derived material according to claim 1 or claim 2.
Method for producing a health food of the present invention described in claim 4 is characterized by blending the amnion-derived raw material obtained by the manufacturing method of the amnion-derived material according to claim 1 or claim 2.
本発明によれば、従来の胎盤由来原料よりもアンチエイジング効果に有用な成分が多く含まれる羊膜由来原料の製造方法、並びに羊膜由来原料が配合された化粧品及び健康食品を提供することができる。 ADVANTAGE OF THE INVENTION According to this invention, the manufacturing method of an amnion origin raw material in which many components useful for an anti-aging effect are contained rather than the conventional placenta origin raw material, and the cosmetics and health food which mix | blended the amnion origin raw material can be provided.
本発明の第１の実施の形態による羊膜由来原料の製造方法は、採集した胎盤及び羊膜を凍結する分離前凍結工程と、分離前凍結工程の後に、胎盤及び羊膜を流水にて解凍する分離前解凍工程と、分離前解凍工程の後に、胎盤及び羊膜の水切りを行う分離前水切工程と、分離前水切工程の後に、胎盤と羊膜を分離する分離工程と、分離工程の後に、羊膜を水洗いする羊膜水洗工程と、羊膜水洗工程の後に、羊膜の水切りを行う羊膜水切工程と、羊膜水切工程の後に、羊膜を細断し、細断した羊膜を再度水切りする羊膜細断工程と、羊膜細断工程の後に、羊膜を凍結する羊膜凍結工程と、羊膜凍結工程の後に、羊膜を解凍する羊膜解凍工程と、羊膜解凍工程の後に、羊膜を分解抽出してエキスを得る抽出工程とを有し、抽出工程は、羊膜に精製水及び中性プロテアーゼを加え、抽出温度を３０度以上７０度以下、抽出時間を１時間以上１０時間以下としたものであり、胎盤及び羊膜は、ウマから採集されたものである。
本実施の形態によれば、従来の胎盤由来原料よりもアンチエイジング効果に有用な成分が多く含まれる羊膜由来原料を提供できる。また、本実施の形態によれば、効率よく羊膜エキスを抽出できる。
The method for producing an amnion-derived material according to the first embodiment of the present invention includes a pre-separation freezing step for freezing the collected placenta and amniotic membrane, and a pre-separation freezing step before the separation for thawing the placenta and amniotic membrane with running water. After the thawing step, the pre-separation thawing step, draining the placenta and the amniotic membrane, the pre-separation draining step, the separation step for separating the placenta and the amniotic membrane, and the separation step, washing the amniotic membrane after the separation step Amniotic water washing process, Amniotic water draining process after amnion water washing process, Amniotic membrane draining process after amnion draining process, Amnion shredding process to shred the amnion and drain the shredded amnion again, Amnion shredding after step, the amnion freezing step of freezing the amniotic membrane, after the amniotic freezing process, possess an amniotic decompression step of decompressing the amniotic membrane, after the amniotic thawing step, an extraction step of the amniotic decomposition extracted to obtain the extract, The extraction process uses purified water on the amniotic membrane. Fine neutral protease was added, extraction temperature of 30 degrees 70 degrees or less is obtained by the extraction time than 1 hour 10 hours or more, placenta and amniotic membrane are those collected from horses.
According to the present embodiment, it is possible to provide an amnion-derived material that contains more components useful for anti-aging effects than conventional placenta-derived materials. Moreover, according to this Embodiment, an amniotic membrane extract can be extracted efficiently.
本発明の第２の実施の形態による羊膜由来原料の製造方法は、採集した胎盤及び羊膜を凍結する分離前凍結工程と、分離前凍結工程の後に、胎盤及び羊膜を流水にて解凍する分離前解凍工程と、分離前解凍工程の後に、胎盤及び羊膜の水切りを行う分離前水切工程と、分離前水切工程の後に、胎盤と羊膜を分離する分離工程と、分離工程の後に、羊膜を水洗いする羊膜水洗工程と、羊膜水洗工程の後に、羊膜の水切りを行う羊膜水切工程と、羊膜水切工程の後に、羊膜を細断し、細断した羊膜を再度水切りする羊膜細断工程と、羊膜細断工程の後に、羊膜を凍結する羊膜凍結工程と、羊膜凍結工程の後に、羊膜を解凍する羊膜解凍工程と、羊膜解凍工程の後に、羊膜を分解抽出してエキスを得る抽出工程とを有し、抽出工程は、羊膜の凍結と融解を所定回数繰り返して水溶性画分を分離するものであり、胎盤及び羊膜は、ウマから採集されたものである。
本実施の形態によれば、従来の胎盤由来原料よりもアンチエイジング効果に有用な成分が多く含まれる羊膜由来原料を提供できる。また、本実施の形態によれば、効率よく羊膜エキスを抽出できる。
The method for producing an amnion-derived raw material according to the second embodiment of the present invention includes a pre-separation freezing step for freezing the collected placenta and amniotic membrane, and a pre-separation freezing step before the separation for thawing the placenta and amniotic membrane with running water. After the thawing step, the pre-separation thawing step, draining the placenta and the amniotic membrane, the pre-separation draining step, the separation step for separating the placenta and the amniotic membrane, and the separation step, washing the amniotic membrane after the separation step Amniotic water washing process, Amniotic water draining process after amnion water washing process, Amniotic membrane draining process after amnion draining process, Amnion shredding process to shred the amnion and drain the shredded amnion again, Amnion shredding After the step, the amniotic membrane freezing step for freezing the amniotic membrane, the amniotic membrane thawing step after the amniotic membrane freezing step, and the extraction step of decomposing and extracting the amniotic membrane to obtain an extract after the amniotic membrane thawing step, The extraction process involves freezing the amniotic membrane and The solution is repeated a predetermined number of times all SANYO separating the water-soluble fraction, placenta and amniotic membrane, Ru der those collected from horses.
According to the present embodiment, it is possible to provide an amnion-derived material that contains more components useful for anti-aging effects than conventional placenta-derived materials. Moreover, according to this Embodiment, an amniotic membrane extract can be extracted efficiently.
本発明の第３の実施形態による化粧品の製造方法は、第１又は第２の実施の形態による羊膜由来原料の製造方法によって得られた羊膜由来原料を配合するものである。
本実施の形態によれば、アンチエイジング効果に優れた化粧品を提供できる。
The third method of manufacturing a cosmetic according to embodiments of the present invention is to blend the amnion-derived raw material obtained by the manufacturing method of the amnion-derived material according to the first or second embodiment.
According to this Embodiment, the cosmetics excellent in the anti-aging effect can be provided.
本発明の第４の実施形態による健康食品の製造方法は、第１又は第２の実施の形態による羊膜由来原料の製造方法によって得られた羊膜由来原料を配合するものである。
本実施の形態によれば、アンチエイジング効果に優れた健康食品を提供できる。
The method of manufacturing health food according to a fourth embodiment of the present invention is to blend the amnion-derived raw material obtained by the manufacturing method of the amnion-derived material according to the first or second embodiment.
According to this Embodiment, the health food excellent in the anti-aging effect can be provided.
以下に、本発明の一実施例による羊膜由来原料の製造方法、並びに羊膜由来原料を配合した化粧品及び健康食品について説明する。 Below, the manufacturing method of the amnion origin raw material by one Example of this invention, and the cosmetics and health food which mix | blended the amnion origin raw material are demonstrated.
図１は、本実施例による羊膜由来原料の製造工程図である。
本実施例による羊膜由来原料（羊膜エキス）の製造方法は、分離前凍結工程１０、分離前解凍工程１１、分離前水切工程１２、分離工程１３、羊膜水洗工程１４、羊膜水切工程１５、羊膜細断工程１６、羊膜凍結工程１７、羊膜解凍工程１８及び抽出工程１９を有する。
FIG. 1 is a production process diagram of an amnion-derived material according to this example.
The manufacturing method of the amniotic membrane-derived raw material (amniotic extract) according to this example is the pre-separation freezing step 10, the pre-separation thawing step 11, the pre-separation draining step 12, the separation step 13, the amnion rinsing step 14, the amnion draining step 15, Cutting step 16, amniotic membrane freezing step 17, amnion thawing step 18 and extraction step 19.
分離前凍結工程１０においては、分娩直後に採集した胎盤及び羊膜を、直ちに約−２０度で凍結する。凍結した胎盤及び羊膜は、所定場所まで輸送し保管する。これにより、採集した胎盤及び羊膜を良好な状態で保管することができる。
なお、採集する胎盤及び羊膜は、ヒト、ブタ、ウマ又はヒツジなどの哺乳類動物のものであればよいが、その中でも安全性に優れ、かつ化粧品及び健康食品の用途に適したブタ又はウマの胎盤及び羊膜とすることが好ましい。
In the pre-separation freezing step 10, the placenta and amniotic membrane collected immediately after delivery are immediately frozen at about -20 degrees. The frozen placenta and amniotic membrane are transported and stored in place. Thereby, the collected placenta and amniotic membrane can be stored in good condition.
The placenta and amniotic membrane to be collected may be those of mammals such as humans, pigs, horses or sheep, and among them, the placenta of pigs or horses that are excellent in safety and suitable for use in cosmetics and health foods. And amniotic membrane is preferred.
分離前解凍工程１１においては、分離前凍結工程１０で凍結した胎盤及び羊膜を容器に入れ、その容器に水を流すことによって胎盤及び羊膜を急速解凍する。分離前解凍工程１１は、分離工程１３を開始する直前に行う。
また、胎盤及び羊膜が解凍された後も水を流し続ける。水を流し続けることにより、胎盤や羊膜に触れる水が常に清浄な状態に保たれ、血液等で汚染された解凍用水が胎盤や羊膜に付着することがない。これにより、羊膜由来原料が化粧品又は健康食品といった最終製品のにおいや色に影響することを防止できる。
In the pre-separation thawing step 11, the placenta and amniotic membrane frozen in the pre-separation freezing step 10 are placed in a container, and the placenta and amniotic membrane are rapidly thawed by flowing water into the container. The pre-separation thawing step 11 is performed immediately before the separation step 13 is started.
Also, water continues to flow after the placenta and amniotic membrane are thawed. By continuing to flow water, the water that touches the placenta and amniotic membrane is always kept clean, and the thawing water contaminated with blood or the like does not adhere to the placenta or amniotic membrane. Thereby, it can prevent that an amnion origin raw material influences the smell and color of final products, such as cosmetics or a health food.
分離前水切工程１２においては、分離前解凍工程１１で解凍した胎盤及び羊膜を、ザル等の水切り容器に入れて水切りする。これにより、余分な水分を除去でき、後工程での作業性が向上する。 In the pre-separation draining step 12, the placenta and the amniotic membrane thawed in the pre-separation thawing step 11 are drained into a draining container such as a monkey. Thereby, excess water can be removed, and workability in the subsequent process is improved.
分離工程１３においては、分離前水切工程１２で水切りした胎盤及び羊膜から羊膜を分離する。
胎盤及び羊膜の形状は動物種によって異なり、例えば、ヒトの場合は子宮の一部に円盤状に形成される盤状胎盤、ブタ及びウマの場合は子宮内の全体に散在して形成される散在性胎盤と呼ばれる構造である。胎盤から羊膜を分離する際は、ヒトの場合は胎盤が一つの大きな塊となっているので作業が明確であるが、散在性胎盤であるブタ及びウマの場合はそうではないため、以下の手順で行う。
まず、胎盤を分離する前の羊膜をハサミなどの切断具で切り開いて伸ばす。次に、胎盤と羊膜を分離する。次に、分離した羊膜に付着した胎盤及び血管を取り残しがないように注意して除去する。これにより、胎盤と羊膜を効率よく分離することができ、胎盤や血管が付着していない羊膜のみを抽出に供することができる。このように分離された羊膜を用いて抽出工程１９で得られた羊膜エキスは、アンチエイジング効果に有用な成分がより多く含まれた羊膜由来原料となる。また、化粧品や健康食品といった最終製品に配合する場合に、最終製品のにおいや色への影響が少ない。
In the separation step 13, the amniotic membrane is separated from the placenta and amniotic membrane drained in the pre-separation draining step 12.
The shape of the placenta and amniotic membrane varies depending on the animal species, for example, the placenta that is formed in a disk shape in the part of the uterus in the case of humans, and the scattered part formed in the whole uterus in the case of pigs and horses It is a structure called the sex placenta. When separating the amniotic membrane from the placenta, the work is clear because the placenta is one large mass in humans, but not in pigs and horses that are scattered placenta. To do.
First, the amniotic membrane before separation of the placenta is opened and stretched with a cutting tool such as scissors. Next, placenta and amnion are separated. Next, the placenta and blood vessels attached to the separated amniotic membrane are carefully removed so as not to leave behind. Thereby, the placenta and the amniotic membrane can be separated efficiently, and only the amniotic membrane to which the placenta and blood vessels are not attached can be used for extraction. The amnion extract obtained in the extraction step 19 using the thus-separated amniotic membrane becomes an amnion-derived raw material containing more components useful for the anti-aging effect. In addition, when blended into final products such as cosmetics and health foods, there is little effect on the odor and color of the final product.
羊膜水洗工程１４においては、分離工程１３で胎盤から分離した羊膜を、再度水洗いする。これにより、分離した羊膜に胎盤や血管が残ることをより確実に防止できる。 In the amnion rinsing step 14, the amnion separated from the placenta in the separation step 13 is washed again with water. This can more reliably prevent the placenta and blood vessels from remaining in the separated amniotic membrane.
羊膜水切工程１５においては、羊膜水洗工程１４で水洗いした羊膜を、ザル等の水切り容器に入れて水切りする。羊膜の水分除去、すなわち羊膜の水分管理を行うことにより、羊膜の重量が水分によってばらつくことを防止し、ひいては羊膜由来原料の品質を向上させることができる。
羊膜水切工程１５の後に羊膜細断工程１６を行う。羊膜細断工程１６で細断した羊膜は、再度水切りする。再度水切りを行うことで水分管理の精度を高め、羊膜の重量の水分によるばらつきを更に抑制し、羊膜由来原料の品質をより一層向上させることができる。
In the amniotic membrane draining step 15, the amniotic membrane washed in the amniotic membrane washing step 14 is put into a draining container such as a colander to drain the water. By removing water from the amniotic membrane, that is, managing the water content of the amniotic membrane, it is possible to prevent the weight of the amniotic membrane from being dispersed by moisture, and to improve the quality of the raw material derived from the amniotic membrane.
The amniotic membrane draining step 15 is followed by the amniotic membrane shredding step 16. The amniotic membrane cut in the amniotic shredding step 16 is drained again. By draining again, the accuracy of moisture management can be increased, variation in the weight of the amniotic membrane due to moisture can be further suppressed, and the quality of the amniotic membrane-derived raw material can be further improved.
羊膜細断工程１６においては、羊膜水切工程１５で水切りした羊膜を、ミンチ機等の細断機で例えば９ｍｍ角に細断する。 In the amniotic shredding step 16, the amniotic membrane drained in the amniotic membrane draining step 15 is shredded into, for example, a 9 mm square with a shredding machine such as a mincing machine.
羊膜凍結工程１７においては、羊膜細断工程１６で細断し水切りした羊膜の重量を測定してポリ袋等の収納容器に入れ、空気抜きをして密封し、すみやかに冷凍庫に入れて約−２０度で羊膜を凍結させる。これにより、細断した羊膜を良好な状態で保管することができる。また、上述のように、羊膜水切工程１５及び羊膜細断工程１６において水分管理を行っているため、測定される羊膜の重量は、水分によるばらつきが抑制されたものである。
なお、例えばウマの胎盤からは、分離前の胎盤に対する重量％で約１５％〜４０％重量の羊膜が得られる。
羊膜凍結工程１７で凍結した羊膜は、羊膜解凍工程１８において解凍する。
In the amniotic membrane freezing step 17, the weight of the amniotic membrane shredded and drained in the amniotic shredding step 16 is measured, put into a storage container such as a plastic bag, air-sealed, sealed, and immediately put in a freezer to be about −20. Freeze the amniotic membrane at a degree. Thereby, the shredded amniotic membrane can be stored in a good state. In addition, as described above, since water management is performed in the amniotic membrane draining step 15 and the amniotic membrane shredding step 16, the weight of the measured amniotic membrane is suppressed from variation due to moisture.
For example, from an equine placenta, an amniotic membrane of about 15% to 40% by weight with respect to the placenta before separation is obtained.
The amniotic membrane frozen in the amniotic membrane freezing step 17 is thawed in the amniotic membrane thawing step 18.
抽出工程１９においては、羊膜解凍工程１８で解凍した羊膜について、酵素処理、加水分解処理、酸処理又は凍結融解等の方法で分解抽出を行う。これにより、羊膜エキスを得ることができる。
抽出工程１９で得られた羊膜エキスを遠心分離又はろ過することにより、化粧品や健康食品等に配合する羊膜エキスの液体原料とすることができる。
また、抽出工程１９で得られた羊膜エキスを凍結乾燥又は噴霧乾燥することにより、化粧品や健康食品等に配合する羊膜エキスの粉末原料とすることができる。
羊膜エキスの液体原料又は粉末原料を所定量配合することにより、胎盤から分離した羊膜のエキスが配合された化粧品又は健康食品を得ることができる。
なお、羊膜解凍工程１８の後、抽出工程１９には移行せず、解凍した羊膜についてフリーズドライ等の乾燥を行って破砕した場合には、羊膜の粉末原料を得ることができる。
In the extraction step 19, the amniotic membrane thawed in the amniotic membrane thawing step 18 is decomposed and extracted by a method such as enzyme treatment, hydrolysis treatment, acid treatment, or freeze- thawing . Thereby, an amniotic membrane extract can be obtained.
By centrifuging or filtering the amniotic membrane extract obtained in the extraction step 19, it can be used as a liquid raw material for the amniotic membrane extract to be blended in cosmetics, health foods and the like.
In addition, the amniotic membrane extract obtained in the extraction step 19 can be freeze-dried or spray-dried to obtain an amnion extract powder material to be blended in cosmetics, health foods, and the like.
By blending a predetermined amount of a liquid raw material or a powder raw material of the amniotic membrane extract, a cosmetic or health food containing the amniotic membrane extract separated from the placenta can be obtained.
After the amniotic membrane thawing step 18, the process does not proceed to the extraction step 19, and when the thawed amniotic membrane is crushed by drying such as freeze-drying, an amnion powder raw material can be obtained.
図２は、図１に示す工程により製造した羊膜エキスの指標成分を酵素免疫測定法により定量した結果を示す図である（単位：pg/g）。
指標成分は、サイトカイン類であるEpidermal Growth Factor（EGF）、acidic Fibroblast Growth Factor（aFGF）、Hepatocyte Growth Factor（HGF）、Growth Differentiation Factor 11（GDF-11）とした。
FIG. 2 is a diagram showing the results of quantifying index components of amniotic membrane extract produced by the process shown in FIG. 1 by enzyme immunoassay (unit: pg / g).
The index components were cytokines such as Epidermal Growth Factor (EGF), acidic Fibroblast Growth Factor (aFGF), Hepatocyte Growth Factor (HGF), and Growth Differentiation Factor 11 (GDF-11).
図２（ａ）は、羊膜エキスの粉末原料の指標成分を定量した結果を示している。羊膜エキスの粉末原料は、羊膜細断工程１６において羊膜をミンチ状に細断した後、羊膜凍結工程１７及び羊膜解凍工程１８を経て、抽出工程１９において精製水と中性プロテアーゼを加えて、抽出温度を３０度以上７０度以下、抽出時間を１時間以上１０時間以下として処理し、得られた羊膜エキスを凍結乾燥することにより製造したものである。由来原料にウマの羊膜を用いた場合を実施例１、ブタの羊膜を用いた場合を実施例２としている。
また、図２（ａ）には、比較例として、胎盤エキスの粉末原料の指標成分を定量した結果を併せて示している。胎盤エキスの粉末原料は、羊膜の代わりに分離前の胎盤を用いた以外は実施例１、２と同条件で処理することにより製造したものである。由来原料にウマの胎盤を用いた場合を比較例１、ブタの胎盤を用いた場合を比較例２としている。
FIG. 2 (a) shows the result of quantifying the index component of the powder raw material of amniotic membrane extract. The raw material of the amniotic extract is extracted by mincing the amniotic membrane in minced step 16 and then passing through amniotic membrane freezing step 17 and amnion thawing step 18 and in extraction step 19 by adding purified water and neutral protease. It is manufactured by treating the temperature at 30 ° C. or higher and 70 ° C. or lower, the extraction time 1 hour or longer and 10 hours or less, and freeze-drying the obtained amniotic membrane extract. Example 1 uses horse equine amniotic membrane as the starting material, and Example 2 uses porcine amniotic membrane.
Moreover, in FIG. 2 (a), the result of having quantified the index component of the powder raw material of a placenta extract is also shown as a comparative example. The placenta extract powder raw material was produced by processing under the same conditions as in Examples 1 and 2 except that the placenta before separation was used instead of the amniotic membrane. The case where the placenta of the horse is used as the source material is Comparative Example 1, and the case where the placenta of the pig is used is Comparative Example 2.
図２（ａ）に示すように、実施例１、２は、比較例１、２に比べて指標成分が高い値でバランスよく検出されていることが分かる。特にGDF-11に関しては、比較例１、２では検出されないか又は検出されても低い値であるのに対して、実施例１、２では高い値が検出されている。これらの指標成分はアンチエイジングに有用な成分であるから、胎盤から分離した羊膜を用いた羊膜エキスの粉末原料を配合することで、羊膜を分離する前の胎盤又は羊膜を分離した後の胎盤を用いた胎盤エキスの粉末原料を配合した場合よりも、アンチエイジング効果に優れた化粧品や健康食品を提供することができる。
また、GDF-11については、実施例２よりも実施例１のほうが高い値となっている。したがって、GDF-11を多く含ませたい場合は、ウマの羊膜エキスの粉末原料を用いることが好ましい。
As shown in FIG. 2A, it can be seen that in Examples 1 and 2, the index component is detected with a high value and a good balance as compared with Comparative Examples 1 and 2. In particular, GDF-11 is not detected in Comparative Examples 1 and 2 or is a low value even if detected, whereas a high value is detected in Examples 1 and 2. Since these indicator components are useful for anti-aging, by mixing the raw material of amniotic extract using amniotic membrane separated from placenta, placenta before separating amniotic membrane or placenta after separating amniotic membrane It is possible to provide cosmetics and health foods that are more excellent in anti-aging effects than when the placenta extract powder raw material used is blended.
For GDF-11, the value in Example 1 is higher than that in Example 2. Therefore, when it is desired to contain a large amount of GDF-11, it is preferable to use a raw material of horse amniotic extract.
図２（ｂ）は、羊膜エキスの液体原料の指標成分を定量した結果を示している。羊膜エキスの液体原料は、羊膜細断工程１６において羊膜をミンチ状に細断した後、羊膜凍結工程１７及び羊膜解凍工程１８を経て、抽出工程１９において凍結と融解を所定回数繰り返して水溶性画分を分離することにより製造したものである。由来原料にウマの羊膜を用いた場合を実施例３、ブタの羊膜を用いた場合を実施例４としている。
また、図２（ｂ）には、比較例として、胎盤エキスの液体原料の指標成分を定量した結果を併せて示している。胎盤エキスの液体原料は、羊膜の代わりに分離前の胎盤を用いた以外は実施例３、４と同条件で処理することにより製造したものである。由来原料にウマの胎盤を用いた場合を比較例３、ブタの胎盤を用いた場合を比較例４としている。
FIG.2 (b) has shown the result of having quantified the index component of the liquid raw material of amniotic membrane extract. The liquid raw material of the amniotic extract is obtained by chopping the amniotic membrane into a minced shape in the amniotic shredding step 16, followed by the amniotic membrane freezing step 17 and the amniotic membrane thawing step 18, and repeating the freezing and thawing a predetermined number of times in the extraction step 19. It was produced by separating the minutes. Example 3 is a case where horse amniotic membrane is used as a source material, and Example 4 is a case where porcine amniotic membrane is used.
Moreover, in FIG.2 (b), the result of having quantified the index component of the liquid raw material of a placenta extract is also shown as a comparative example. The liquid material of placenta extract was produced by processing under the same conditions as in Examples 3 and 4 except that the placenta before separation was used instead of amniotic membrane. The case where the equine placenta is used as the source material is Comparative Example 3, and the case where the pig placenta is used is Comparative Example 4.
図２（ｂ）に示すように、実施例３、４は、比較例３、４に比べて指標成分が高い値でバランスよく検出されていることが分かる。特にGDF-11に関しては、比較例３、４では検出されないか又は検出されても低い値であるのに対して、実施例３、４では高い値が検出されている。これらの指標成分はアンチエイジングに有用な成分であるから、胎盤から分離した羊膜を用いた羊膜エキスの液体原料を配合することで、羊膜を分離する前の胎盤又は羊膜を分離した後の胎盤を用いた胎盤エキスの液体原料を配合した場合よりも、アンチエイジング効果に優れた化粧品や健康食品を提供することができる。
また、GDF-11については、実施例４よりも実施例３のほうが高い値となっている。したがって、GDF-11を多く含ませたい場合は、ウマの羊膜エキスの液体原料を用いることが好ましい。
As shown in FIG. 2B, it can be seen that in Examples 3 and 4, the index component is detected in a well-balanced manner with a higher value than Comparative Examples 3 and 4. In particular, GDF-11 is not detected in Comparative Examples 3 and 4 or is a low value even if it is detected, whereas a high value is detected in Examples 3 and 4. Since these indicator components are useful for anti-aging, by adding the amniotic extract liquid material using amniotic membrane separated from placenta, placenta before separating amniotic membrane or placenta after separating amniotic membrane It is possible to provide cosmetics and health foods that are more excellent in anti-aging effect than when the liquid material of the placenta extract used is blended.
For GDF-11, the value in Example 3 is higher than that in Example 4. Therefore, when it is desired to contain a large amount of GDF-11, it is preferable to use a liquid raw material of horse amniotic extract.
図３は、図１に示す工程により製造した羊膜エキスの角質水分量保持データを示す図である。横軸は経過時間（min）、縦軸は角質水分量（μｓ）である。
図中「▲」は、羊膜細断工程１６においてウマの羊膜をミンチ状に細断した後、羊膜凍結工程１７及び羊膜解凍工程１８を経て、抽出工程１９において精製水と中性プロテアーゼを加えて、抽出温度を３０度以上７０度以下、抽出時間を１時間以上１０時間以下として処理し、０．２μｍのろ過を行うことにより製造した羊膜エキスのデータである（実施例５）。
また、図中「■」及び「◆」は、比較例のデータである。「■」は、ウマの胎盤を処理して得られた胎盤エキスのデータを示し（比較例５）、「◆」は、羊膜エキスも胎盤エキスも含まれていない無添加のコントロール（水）のデータを示している（比較例６）。なお、比較例５の胎盤エキスは、羊膜の代わりに胎盤を用いた以外は実施例５と同条件で処理することにより製造したものである。
FIG. 3 is a diagram showing keratin water content retention data of the amniotic membrane extract produced by the process shown in FIG. The horizontal axis represents elapsed time (min), and the vertical axis represents keratin water content (μs).
In the figure, “▲” indicates that the horse's amniotic membrane is shredded into mince in the amniotic shredding step 16, followed by the amniotic membrane freezing step 17 and the amniotic membrane thawing step 18, and purified water and neutral protease are added in the extraction step 19. This is data of an amniotic extract produced by treating the extraction temperature at 30 ° C. or higher and 70 ° C. or lower, the extraction time 1 hour or longer and 10 hours or less, and performing 0.2 μm filtration (Example 5).
In the figure, “■” and “♦” are data of the comparative example. “■” indicates data of placenta extract obtained by treating horse placenta (Comparative Example 5), and “◆” indicates an additive-free control (water) containing neither amniotic extract nor placenta extract. Data are shown (Comparative Example 6). The placenta extract of Comparative Example 5 was produced by treatment under the same conditions as Example 5 except that placenta was used instead of amniotic membrane.
図３に示すように、実施例５の羊膜エキスは、塗布してから９０分以降、比較例５の胎盤エキスを塗布した場合と比べて角質水分量が上回っており、比較例５の胎盤エキスよりも持続的な保湿力を有していることが分かる。 As shown in FIG. 3, the amniotic membrane extract of Example 5 has a keratinous water content exceeding 90 minutes after application, compared with the case where the placenta extract of Comparative Example 5 is applied. It turns out that it has more continuous moisturizing power.
図４は、図１に示す工程により製造した羊膜エキスの使用感テストの結果を示す図である。
使用感テストは、羊膜エキスが１％配合された化粧水について、ヒトモニター１０名を対象として一ヶ月行い、「しっとり」、「ハリ」、「つや」及び「やわらかさ」の各項目について評価を得た。
使用感テストに使用した羊膜エキスは、由来原料をウマの羊膜とし、羊膜細断工程１６において羊膜をミンチ状に細断した後、羊膜凍結工程１７及び羊膜解凍工程１８を経て、抽出工程１９において精製水と中性プロテアーゼを加えて、抽出温度を３０度以上７０度以下、抽出時間を１時間以上１０時間以下として処理し、０．２μｍのろ過を行うことにより製造したものである。
FIG. 4 is a diagram showing the results of a usability test of the amniotic membrane extract produced by the process shown in FIG.
The usability test is conducted for a month on 10 human monitors with lotion containing 1% amniotic membrane extract and evaluated for each item of "Moist", "Hari", "Glossy" and "Softness". Obtained.
The amniotic membrane extract used in the usability test is equine amniotic membrane, and the amniotic membrane is shredded into mince in the amniotic shredding step 16, followed by the amniotic membrane freezing step 17 and the amniotic membrane thawing step 18, and in the extraction step 19 It is produced by adding purified water and neutral protease, treating the extraction temperature at 30 ° C. or more and 70 ° C. or less, the extraction time at 1 hour or more and 10 hours or less, and performing 0.2 μm filtration.
図４に示すように、「しっとり（保湿効果）」、「ハリ」、「つや」及び「やわらかさ」のいずれにおいても向上効果が確認された。 As shown in FIG. 4, the improvement effect was confirmed in any of “moisturizing (moisturizing effect)”, “harness”, “gloss”, and “softness”.
図５は、図１に示す工程により製造した羊膜エキスを手の甲に塗布した場合の効果を示す図である（実施例６）。また、図６は、比較例として胎盤エキスを手の甲に塗布した場合の効果を示す図である（比較例７）。また、図７は、図１に示す工程により製造した羊膜エキスを足に塗布した場合の効果を示す図である（実施例７）。
実施例６、７の羊膜エキスは、由来原料をウマの羊膜とし、羊膜細断工程１６において羊膜をミンチ状に細断した後、羊膜凍結工程１７及び羊膜解凍工程１８を経て、抽出工程１９において精製水と中性プロテアーゼを加えて、抽出温度を３０度以上７０度以下、抽出時間を１時間以上１０時間以下として処理し、０．２μｍのろ過を行うことにより製造したものである。
また、比較例７の胎盤エキスは、羊膜の代わりに胎盤を用いた以外は羊膜エキスと同条件で処理することにより製造したものである。
効果は、羊膜エキスを塗布する群としてヒトモニターＡ〜Ｅの５名、胎盤エキスを塗布する群としてヒトモニターＦ〜Ｊの５名を対象として、以下の手順にて５日間行うことで確認した。
１．塗布前に肌の肌理を撮影する。
２．その後、１日１回手の甲に羊膜エキス又は胎盤エキスを塗布する。なお、ヒトモニターＡについては、足にも羊膜エキスを塗布する。
３．最終日の同時間に再度肌の肌理を撮影する。
FIG. 5 is a view showing the effect when the amniotic membrane extract produced by the process shown in FIG. 1 is applied to the back of the hand (Example 6). Moreover, FIG. 6 is a figure which shows the effect at the time of apply | coating a placenta extract to the back of a hand as a comparative example (comparative example 7). Moreover, FIG. 7 is a figure which shows the effect at the time of apply | coating the amniotic membrane extract manufactured by the process shown in FIG. 1 to a leg (Example 7).
The amniotic membrane extract of Examples 6 and 7 was horse amniotic membrane as a starting material, and the amniotic membrane was shredded into minced in the amniotic shredding step 16, then passed through the amniotic membrane freezing step 17 and the amniotic membrane thawing step 18, and in the extraction step 19 It is produced by adding purified water and neutral protease, treating the extraction temperature at 30 ° C. or more and 70 ° C. or less, the extraction time at 1 hour or more and 10 hours or less, and performing 0.2 μm filtration.
The placenta extract of Comparative Example 7 was produced by processing under the same conditions as the amniotic membrane extract, except that the placenta was used instead of the amniotic membrane.
The effect was confirmed by carrying out the following procedure for 5 days for 5 people of human monitors A to E as a group to apply amniotic membrane extract and 5 people of human monitors F to J as a group to apply placenta extract. .
1. Photograph skin texture before application.
2. Thereafter, amniotic extract or placenta extract is applied to the back of the hand once a day. For human monitor A, the amniotic membrane extract is also applied to the feet.
3. Take the skin texture again at the same time on the last day.
図５及び図６においては、ヒトモニターごとに肌理の状態を示している。図５（ａ）〜（ｅ）はそれぞれヒトモニターＡ〜Ｅの肌理の状態を示し、図６（ａ）〜（ｅ）はそれぞれヒトモニターＦ〜Ｊの肌理の状態を示しており、各（ａ）〜（ｅ）において、左側が塗布前の肌理の状態、右側が最終日の肌理の状態である。
図５及び図６に示すように、羊膜エキスを手の甲に塗布した結果、胎盤エキスを手の甲に塗布した結果と同等以上に、肌のきめ細かさが向上することが確認された。
5 and 6 show the state of the texture for each human monitor. FIGS. 5 (a) to (e) show the texture of human monitors A to E, respectively, and FIGS. 6 (a) to (e) show the texture of human monitors F to J, respectively. In a) to (e), the left side is the state of texture before application, and the right side is the state of texture on the last day.
As shown in FIGS. 5 and 6, as a result of applying the amniotic membrane extract to the back of the hand, it was confirmed that the fineness of the skin was improved to be equal to or higher than the result of applying the placenta extract to the back of the hand.
図７（ａ）においては、ヒトモニターＡについて、左側が塗布前の肌理の状態、右側が最終日の肌理の状態である。また、図７（ｂ）においては、上段が初日の塗布前の肌の状態を示し、下段が最終日の肌の状態を示している。
図７（ａ）に示すように、羊膜エキスを足に塗布した結果、肌の乾燥が改善し肌のきめ細かさが向上することが確認された。
また、図７（ｂ）に示すように、羊膜エキスを足に塗布した結果、湿疹が改善することが確認された。
In FIG. 7A, regarding the human monitor A, the left side is the textured state before application, and the right side is the textured state of the last day. Moreover, in FIG.7 (b), the upper stage shows the skin state before application | coating of the first day, and the lower stage has shown the skin state of the last day.
As shown to Fig.7 (a), as a result of apply | coating an amniotic membrane extract to a leg | foot, it was confirmed that dryness of skin improves and the fineness of skin improves.
Moreover, as shown in FIG.7 (b), it was confirmed that eczema improves as a result of applying amniotic membrane extract to a leg.
図８は、図１に示す工程により製造した羊膜エキスの飲用テストの結果を示す図である。
飲用テストは、ウマの羊膜エキスの粉末原料をハードカプセルに充填した健康食品（実施例８）と、ウマの胎盤エキスの粉末原料をハードカプセルに充填した健康食品（比較例８）について、ヒトモニター１０名を対象として計１０日間行い、「飲みやすさ」、「におい」、「体調の良い変化」、「肌の潤い」、「肌のハリ・弾力」及び「肌のキメ」の各項目について評価を得た。
飲用テストに使用した羊膜エキスの粉末原料は、由来原料をウマの羊膜とし、羊膜細断工程１６において羊膜をミンチ状に細断した後、羊膜凍結工程１７及び羊膜解凍工程１８を経て、抽出工程１９において精製水と中性プロテアーゼを加えて、抽出温度を３０度以上７０度以下、抽出時間を１時間以上１０時間以下として処理し、得られた羊膜エキスを凍結乾燥することにより製造したものである。また、胎盤エキスの粉末原料は、羊膜の代わりに胎盤を用いた以外は実施例８と同条件で処理することにより製造したものである。
飲用テストは、以下の方法で行い、各項目について実施例８と比較例８のどちらが優れているかをヒトモニターに選択してもらった。
第１グループ（ヒトモニター５名）：（１）実施例８の健康食品を５日間飲用→（２）比較例８の健康食品を５日間飲用（計１ヶ月となるまで（１）と（２）を繰り返す）
第２グループ（ヒトモニター５名）：（１）比較例８の健康食品を５日間飲用→（２）実施例８の健康食品を５日間飲用（計１ヶ月となるまで（１）と（２）を繰り返す）
FIG. 8 is a diagram showing the results of a drinking test of amniotic membrane extract produced by the process shown in FIG.
The drinking test consisted of 10 human monitors for a health food (Example 8) filled with hard capsules of horse amnion extract powder material and a health food (Comparative Example 8) filled with powdered horse placenta extract powder materials. For a total of 10 days, and evaluate each item of “ease of drinking”, “smell”, “good physical condition”, “moisturizing skin”, “skin elasticity / elasticity” and “skin texture” Obtained.
The raw material of the amniotic extract used in the drinking test was horse amniotic membrane derived from the raw material, and the amniotic membrane was shredded into mince in the amniotic shredding step 16, followed by the amniotic membrane freezing step 17 and the amniotic membrane thawing step 18, followed by the extraction step In 19, purified water and neutral protease were added, the extraction temperature was 30 ° C. to 70 ° C., the extraction time was 1 hour to 10 hours, and the resulting amniotic membrane extract was freeze-dried. is there. Moreover, the powder raw material of a placenta extract is manufactured by processing on the same conditions as Example 8 except having used the placenta instead of the amniotic membrane.
The drinking test was performed by the following method, and the human monitor selected which of Example 8 and Comparative Example 8 was superior for each item.
Group 1 (5 human monitors): (1) Drinking health food of Example 8 for 5 days → (2) Drinking health food of Comparative Example 8 for 5 days (until 1 month in total (1) and (2 )repeat)
Second group (5 human monitors): (1) The health food of Comparative Example 8 was drunk for 5 days → (2) The health food of Example 8 was drunk for 5 days (until 1 month in total (1) and (2 )repeat)
図８に示すように、実施例８の羊膜エキスは、「飲みやすさ」、「におい」及び「肌の潤い」の項目において比較例８の胎盤エキスと同等の体感が得られ、「体調の良い変化」、「肌のハリ・弾力」及び「肌のキメ」において比較例８の胎盤エキスよりも体感の向上効果が確認された。 As shown in FIG. 8, the amniotic membrane extract of Example 8 has a body sensation equivalent to that of the placenta extract of Comparative Example 8 in the items of “ease of drinking”, “odor” and “moisturizing skin”. In the “good change”, “skin elasticity / elasticity” and “skin texture”, the effect of improving the bodily sensation was confirmed as compared with the placenta extract of Comparative Example 8.
本発明の羊膜由来原料の製造方法によれば、従来の胎盤由来原料よりもアンチエイジング効果に有用な成分が多く含まれる羊膜由来原料を提供することができる。また、この羊膜由来原料が配合された化粧品や健康食品等を提供することができる。 According to the method for producing an amnion-derived material of the present invention, it is possible to provide an amnion-derived material that contains more components useful for the anti-aging effect than conventional placenta-derived materials. In addition, cosmetics, health foods and the like in which this amniotic membrane-derived material is blended can be provided.
１０ 分離前凍結工程
１１ 分離前解凍工程
１２ 分離前水切工程
１３ 分離工程
１４ 羊膜水洗工程
１５ 羊膜水切工程
１６ 羊膜細断工程
１７ 羊膜凍結工程
１８ 羊膜解凍工程
１９ 抽出工程
10 Freezing process before separation
11 Thawing process before separation
12 Draining process before separation
13 Separation process 14 Amniotic water washing process 15 Amniotic membrane draining process 16 Amniotic membrane shredding process 17 Amniotic membrane freezing process 18 Amniotic membrane thawing process 19 Extraction process
Claims (4)
前記分離前凍結工程の後に、前記胎盤及び前記羊膜を流水にて解凍する分離前解凍工程と、
前記分離前解凍工程の後に、前記胎盤及び前記羊膜の水切りを行う分離前水切工程と、
前記分離前水切工程の後に、前記胎盤と前記羊膜を分離する分離工程と、
前記分離工程の後に、前記羊膜を水洗いする羊膜水洗工程と、
前記羊膜水洗工程の後に、前記羊膜の水切りを行う羊膜水切工程と、
前記羊膜水切工程の後に、前記羊膜を細断し、細断した前記羊膜を再度水切りする羊膜細断工程と、
前記羊膜細断工程の後に、前記羊膜を凍結する羊膜凍結工程と、
前記羊膜凍結工程の後に、前記羊膜を解凍する羊膜解凍工程と、
前記羊膜解凍工程の後に、前記羊膜を分解抽出してエキスを得る抽出工程とを有し、
前記抽出工程は、前記羊膜に精製水及び中性プロテアーゼを加え、抽出温度を３０度以上７０度以下、抽出時間を１時間以上１０時間以下としたものであり、
前記胎盤及び前記羊膜は、ウマから採集されたものであることを特徴とする羊膜由来原料の製造方法。 A pre-separation freezing step of freezing the collected placenta and amniotic membrane;
After the pre-separation freezing step, a pre-separation thawing step for thawing the placenta and the amniotic membrane with running water;
A pre-separation draining step of draining the placenta and the amniotic membrane after the pre-separation thawing step;
A separation step of separating the placenta and the amniotic membrane after the pre-separation draining step;
An amnion rinsing step of washing the amniotic membrane with water after the separation step;
An amnion draining step of draining the amniotic membrane after the amnion rinsing step;
After the amniotic membrane draining step, the amniotic membrane is shredded, and the amniotic membrane shredding step of draining the shredded amniotic membrane again ;
An amniotic membrane freezing step of freezing the amniotic membrane after the amniotic membrane shredding step;
An amnion thawing step for thawing the amnion after the amnion freezing step ;
After said amnion thawing step, the amnion decomposition extracted and possess an extraction step of obtaining a extract,
In the extraction step, purified water and neutral protease are added to the amniotic membrane, the extraction temperature is 30 to 70 degrees, and the extraction time is 1 to 10 hours,
The placenta and the amniotic membrane are collected from horses .
前記分離前凍結工程の後に、前記胎盤及び前記羊膜を流水にて解凍する分離前解凍工程と、
前記分離前解凍工程の後に、前記胎盤及び前記羊膜の水切りを行う分離前水切工程と、
前記分離前水切工程の後に、前記胎盤と前記羊膜を分離する分離工程と、
前記分離工程の後に、前記羊膜を水洗いする羊膜水洗工程と、
前記羊膜水洗工程の後に、前記羊膜の水切りを行う羊膜水切工程と、
前記羊膜水切工程の後に、前記羊膜を細断し、細断した前記羊膜を再度水切りする羊膜細断工程と、
前記羊膜細断工程の後に、前記羊膜を凍結する羊膜凍結工程と、
前記羊膜凍結工程の後に、前記羊膜を解凍する羊膜解凍工程と、
前記羊膜解凍工程の後に、前記羊膜を分解抽出してエキスを得る抽出工程とを有し、
前記抽出工程は、前記羊膜の凍結と融解を所定回数繰り返して水溶性画分を分離するものであり、
前記胎盤及び前記羊膜は、ウマから採集されたものであることを特徴とする羊膜由来原料の製造方法。 A pre-separation freezing step of freezing the collected placenta and amniotic membrane;
After the pre-separation freezing step, a pre-separation thawing step for thawing the placenta and the amniotic membrane with running water;
A pre-separation draining step of draining the placenta and the amniotic membrane after the pre-separation thawing step;
A separation step of separating the placenta and the amniotic membrane after the pre-separation draining step;
An amnion rinsing step of washing the amniotic membrane with water after the separation step;
An amnion draining step of draining the amniotic membrane after the amnion rinsing step;
After the amniotic membrane draining step, the amniotic membrane is shredded, and the amniotic membrane shredding step of draining the shredded amniotic membrane again;
An amniotic membrane freezing step of freezing the amniotic membrane after the amniotic membrane shredding step;
An amnion thawing step for thawing the amnion after the amnion freezing step;
An extraction step of decomposing and extracting the amniotic membrane to obtain an extract after the amnion thawing step;
The extraction process state, and are not to separate the water-soluble fraction by repeating a predetermined number of times freezing and thawing of the amniotic membrane,
The placenta and the amnion method of amnion-derived materials characterized der Rukoto those collected from horses.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017093908A JP6373444B1 (en) | 2017-05-10 | 2017-05-10 | Amnion-derived raw material manufacturing method, cosmetic manufacturing method, and health food manufacturing method |
| TW107114430A TWI688393B (en) | 2017-05-10 | 2018-04-27 | Manufacturing method of raw materials derived from amniotic membrane, manufacturing method of cosmetics, and manufacturing method of health food |
| PCT/JP2018/017891 WO2018207810A1 (en) | 2017-05-10 | 2018-05-09 | Method for producing amnion-derived raw material, method for producing cosmetic, and method for producing health food |
| RU2019114695A RU2733542C1 (en) | 2017-05-10 | 2018-05-09 | Methods for producing raw material from amniotic membrane, method for producing cosmetic agent and method for producing healthy food products |
| KR1020187035231A KR102104196B1 (en) | 2017-05-10 | 2018-05-09 | Manufacturing method of raw materials derived from amniotic membrane, manufacturing method of cosmetics, and manufacturing method of health food |
| CN201880000939.4A CN109247011B (en) | 2017-05-10 | 2018-05-09 | Method for producing amnion-derived material and method for producing health food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017093908A JP6373444B1 (en) | 2017-05-10 | 2017-05-10 | Amnion-derived raw material manufacturing method, cosmetic manufacturing method, and health food manufacturing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP6373444B1 true JP6373444B1 (en) | 2018-08-15 |
| JP2018188401A JP2018188401A (en) | 2018-11-29 |
Family
ID=63165915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017093908A Active JP6373444B1 (en) | 2017-05-10 | 2017-05-10 | Amnion-derived raw material manufacturing method, cosmetic manufacturing method, and health food manufacturing method |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP6373444B1 (en) |
| KR (1) | KR102104196B1 (en) |
| CN (1) | CN109247011B (en) |
| RU (1) | RU2733542C1 (en) |
| TW (1) | TWI688393B (en) |
| WO (1) | WO2018207810A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6944606B1 (en) * | 2021-03-30 | 2021-10-06 | 新日本製薬株式会社 | Manufacturing method of cosmetic composition |
| JP2023101072A (en) * | 2022-01-07 | 2023-07-20 | 株式会社ホルス | Method for producing extract, method for producing cosmetic, and method for producing substance for oral use |
| KR102503124B1 (en) * | 2022-08-18 | 2023-02-23 | 주식회사 에이바이오머티리얼즈 | Method for preparing sheep placenta extract containing high content of amino acid and cosmetic composition comprising the extract |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004097033A (en) * | 2002-09-05 | 2004-04-02 | Eiji Kimoto | Method for producing placental extract |
| JP2006045070A (en) * | 2004-07-30 | 2006-02-16 | Hiroshi Hara | Tissue therapy by using placenta |
| JP2009510091A (en) * | 2005-09-27 | 2009-03-12 | ティッシュテク・インコーポレーテッド | Amnion preparation and purified composition and method of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2801313A1 (en) * | 1999-05-19 | 2001-05-25 | Coletica | COLLAGENIC PRODUCT CONTAINING COLLAGEN OF MARINE ORIGIN WITH LOW ODOR AND PREFERREDLY WITH IMPROVED MECHANICAL PROPERTIES, AS WELL AS ITS USE IN THE FORM OF COMPOSITIONS OR COSMETIC OR PHARMACEUTICAL PRODUCTS |
| JP2001039879A (en) | 1999-07-30 | 2001-02-13 | Koji Murata | Antiallergic agent obtained by purification of placenta extract and production of the allergic agent |
| AU2003272536A1 (en) * | 2002-09-18 | 2004-04-08 | Emiliano Ghinelli | Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin |
| RU2252017C1 (en) * | 2004-06-22 | 2005-05-20 | Государственное образовательное учреждение высшего профессионального образования "Сибирский государственный технологический университет" | Cosmetic preparation and method for its obtaining |
| KR101140573B1 (en) * | 2009-06-24 | 2012-05-02 | 농업회사법인 제주마산업 주식회사 | External Skin Preparation Using an Extract of Horse Plancenta |
| US20140286911A1 (en) * | 2013-03-15 | 2014-09-25 | Allosource | Cell repopulated collagen matrix for soft tissue repair and regeneration |
| JP2011160742A (en) | 2010-02-12 | 2011-08-25 | Yamamoto Kenji | Method for producing placenta extract |
| WO2012033352A2 (en) * | 2010-09-08 | 2012-03-15 | 주식회사 강스템홀딩스 | Equine amniotic fluid derived multipotent stem cells and a production method therefor |
| CN102225217A (en) * | 2011-06-23 | 2011-10-26 | 天津世纪康泰生物医学工程有限公司 | Preparation method of acellular dried active amnion |
| KR101906156B1 (en) * | 2011-11-22 | 2018-10-12 | 주식회사 강스템바이오텍 | Equine Amniotic Membrane-Derived Mesenchymal Stem Cells |
| CN103789258A (en) * | 2012-11-30 | 2014-05-14 | 陆华 | Separation method for human amniotic mesenchymal stem cells |
| CN103446184A (en) * | 2013-08-16 | 2013-12-18 | 南京医科大学 | Application of amniotic mesenchymal stem cells in preparation of medicine for prolonging life, health product or cosmetic |
| JP6282243B2 (en) * | 2015-03-11 | 2018-02-21 | 株式会社ホルス | Method for producing fermentation-aged placenta solution |
| CN104974980B (en) * | 2015-05-21 | 2018-06-22 | 重庆市细胞生物工程技术有限公司 | A kind of separation method of human amniotic membrane epithelial cell |
| MA45272A (en) * | 2015-06-27 | 2018-05-02 | Stimlabs Llc | AMNIOTIC FLUID PRODUCTS AND METHODS OF USE |
| CN105062959A (en) * | 2015-09-20 | 2015-11-18 | 领航干细胞再生医学工程有限公司 | Isolated culture method of human amnia mesenchymal stem cells |
-
2017
- 2017-05-10 JP JP2017093908A patent/JP6373444B1/en active Active
-
2018
- 2018-04-27 TW TW107114430A patent/TWI688393B/en active
- 2018-05-09 RU RU2019114695A patent/RU2733542C1/en active
- 2018-05-09 WO PCT/JP2018/017891 patent/WO2018207810A1/en active Application Filing
- 2018-05-09 KR KR1020187035231A patent/KR102104196B1/en active IP Right Grant
- 2018-05-09 CN CN201880000939.4A patent/CN109247011B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004097033A (en) * | 2002-09-05 | 2004-04-02 | Eiji Kimoto | Method for producing placental extract |
| JP2006045070A (en) * | 2004-07-30 | 2006-02-16 | Hiroshi Hara | Tissue therapy by using placenta |
| JP2009510091A (en) * | 2005-09-27 | 2009-03-12 | ティッシュテク・インコーポレーテッド | Amnion preparation and purified composition and method of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109247011A (en) | 2019-01-18 |
| KR102104196B1 (en) | 2020-04-23 |
| WO2018207810A1 (en) | 2018-11-15 |
| TW201900189A (en) | 2019-01-01 |
| RU2733542C1 (en) | 2020-10-05 |
| KR20190005926A (en) | 2019-01-16 |
| CN109247011B (en) | 2021-11-23 |
| TWI688393B (en) | 2020-03-21 |
| JP2018188401A (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102560013B1 (en) | Methods for Producing One or More Products of Interest from Insects by Chitin, Hydrolysates, and Enzymatic Hydrolysis | |
| US11884953B2 (en) | Method for preparing protein peptide based on connective tissue and prepared protein peptide and use thereof | |
| JP6117456B1 (en) | Wrinkle improving composition containing placenta-derived component | |
| JP6373444B1 (en) | Amnion-derived raw material manufacturing method, cosmetic manufacturing method, and health food manufacturing method | |
| CN106011208A (en) | Method for preparing small-molecular weight collagen active peptide through enzymolysis of yak bone and skin | |
| CN106821939A (en) | The extracting method of sheep embryo extract and the preparation containing its extract | |
| JP2008110927A (en) | Cosmetic containing royal jelly protein hydrolyzate | |
| JP2011190217A (en) | Human epidermal cell growth promoter, and skin care composition for external use and cosmetic each containing the same | |
| JP2010077028A (en) | Food for preventing dental caries and oral cavity-caring agent composition | |
| JP2006232693A (en) | Animal-derived extract composition, method for producing the same, and cosmetic composition | |
| JP6326413B2 (en) | Pentosidine production inhibitor | |
| KR101618726B1 (en) | Method for making protein from Pollock skin | |
| KR102151501B1 (en) | Composition for improving hair and head skin | |
| RU2718862C1 (en) | Fish scale processing method for production of functional beverage, functional food additive and cosmetic scrub | |
| KR20070052248A (en) | The composition for natural hair growth promoting agents | |
| CA3034720A1 (en) | Process for isolating bioactive biomolecules from animal by-products | |
| WO2023132120A1 (en) | Method for producing extract, method for producing cosmetic, and method for producing substance for oral use | |
| JP2011236131A (en) | Insoluble collagen-containing powder originated from fish scale | |
| KR20200027140A (en) | Cosmetic composition comprising natural fermented extracts and preparation method of the same | |
| JP2018011569A (en) | Food composition for hair scalp state improvement | |
| KR102483898B1 (en) | Natural flour soap composition containing rice bran oil and manufacturing method thereof | |
| RU2241474C1 (en) | Placental preparation and methods for its obtaining | |
| JP6846700B2 (en) | Hyaluronan synthase gene expression promoter | |
| US565329A (en) | Digestive compound | |
| RU2164142C1 (en) | Method of preparing biologically-active preparation for normalization of physiological condition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180126 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20180126 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20180208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180420 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180619 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180717 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6373444 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |